Best of ASCO - 2014 Annual Meeting

 

Welcome

Publication-only abstracts (abstract number preceded by an "e"), published in conjunction with the 2019 ASCO Annual Meeting but not presented at the Meeting, can be found online only.

Survival analysis of anticoagulant treatment of non-small cell lung cancer.

Sub-category:
Metastatic Non-Small Cell Lung Cancer

Category:
Lung Cancer—Non-Small Cell Metastatic

Meeting:
2019 ASCO Annual Meeting

Abstract No:
e20623

Citation:
J Clin Oncol 37, 2019 (suppl; abstr e20623)

Author(s): Junyan Wang, Fan Zhang, Lei Hong, Da Jiang, Minting Ma, Suju Wei; Department of Medical Oncology, the Fourth Hospital of Hebei Medical University, Shijia Zhuang, China; Department of Medical Oncology, the Fourth Hospital of Hebei Medical University, Shijiazhuang, China; Fourth Hospital of Hebei Medical University, Shijiazhuang, China

Abstract Disclosures

Abstract:

Background: More and more evidence shows that coagulation cascade reaction and some vascular factors can promote the deterioration of tumor. Preventive interventions for high-risk patients with venous thromboembolism can reduce cancer mortality and improve quality of life. Anticoagulants have anti-tumor activity and can participate in the process of adhesion, metastasis, invasion, thrombogenesis and immune escape of cancer cells. So we want to explore the effects of anticoagulants on the survival of patients with non-small cell lung cancer. Methods: This study retrospectively analyzed the clinical data of876 cases with non-small cell lung cancer. According to whether or not to apply anticoagulant drugs, it was divided into 2 groups including application group (270 cases) and non-application group (606 cases), and the survival status of the two groups were followed up. Results: The median survival ofthe non-application group was 14.2 months, the 1, 2, 3, and 5 years survival rates of patients were 56.6%, 31.8%, 21.0% and 6% respectively. The application group median survival of the application group was 17.7 months, the 1, 2, 3, and 5 years survival rates of patients were 66.6%, 36.6%, 28.8% and 16.8% respectively. The median OS and survival rate were extended in anticoagulation group compared with another. The overall comparison of the survival curves of the two groups by Log Rank was P = 0.016. Conclusions: Anticoagulant therapy can significantly improve the overall survival of patients with non-small cell lung cancer.

 
Other Abstracts in this Sub-Category:

 

1. Association of STK11/LKB1 genomic alterations with lack of benefit from the addition of pembrolizumab to platinum doublet chemotherapy in non-squamous non-small cell lung cancer.

Meeting: 2019 ASCO Annual Meeting Abstract No: 102 First Author: Ferdinandos Skoulidis
Category: Lung Cancer—Non-Small Cell Metastatic - Metastatic Non-Small Cell Lung Cancer

 

2. Real-world outcomes of patients with advanced non-small cell lung cancer (aNSCLC) and autoimmune disease (AD) receiving immune checkpoint inhibitors (ICIs).

Meeting: 2019 ASCO Annual Meeting Abstract No: 110 First Author: Sean Khozin
Category: Lung Cancer—Non-Small Cell Metastatic - Metastatic Non-Small Cell Lung Cancer

 

3. RELAY: A multinational, double-blind, randomized Phase 3 study of erlotinib (ERL) in combination with ramucirumab (RAM) or placebo (PL) in previously untreated patients with epidermal growth factor receptor mutation-positive (EGFRm) metastatic non-small cell lung cancer (NSCLC).

Meeting: 2019 ASCO Annual Meeting Abstract No: 9000 First Author: Kazuhiko Nakagawa
Category: Lung Cancer—Non-Small Cell Metastatic - Metastatic Non-Small Cell Lung Cancer

 

More...